RSV NEWCO
RSV NewCo is developing a safe, effective treatment for Respiratory Syncytial Virus (RVS), one of the leading causes of virus-related death for infants, particularly premature infants. Elderly people are also at risk from RSV.
RSV NEWCO
Industry:
Health Care Health Diagnostics Medical Medical Device
Status:
Active
Total Funding:
50 K USD
Similar Organizations
Neurava
Neurava is working to develop a first of its kind, wearable diagnostic for epilepsy patients, including those at risk of SUDEP.
Quantitative Radiology Solutions
Quantitative Radiology Solutions offers advanced body-wide quantification of medical images.
RightAir
RightAir is developing noninvasive ventilators for COPD patients.
VigorSential
VigorSential is Testing and developing a low-dose vaccine to control a bacterium mainly affecting cattle.
Xip
Xip produces disposable blood analyzers that wirelessly upload lab-quality clinical measurements in minutes.
Investors List
Georgia Research Alliance
Georgia Research Alliance investment in Grant - RSV NewCo
More informations about "RSV NewCo"
How to access the new RSV vaccine, and how much will …
Dec 10, 2023 · This year, for the first time, a vaccine is available to help protect older adults against RSV, which is like the common cold for some but can also lead to respiratory infection and...See details»
Summary: Statement on the prevention of respiratory syncytial …
On July 12, 2024, the Public Health Agency of Canada (PHAC) released the National Advisory Committee on Immunization’s (NACI) Statement on the prevention of respiratory syncytial …See details»
Statement on the prevention of respiratory syncytial virus disease …
Jul 12, 2024 · Respiratory syncytial virus (RSV) is a common respiratory virus, and infants and older adults are at higher risk due to RSV. RSV can cause serious respiratory disease in older …See details»
Statement on the prevention of respiratory syncytial virus disease …
May 17, 2024 · Respiratory syncytial virus (RSV) is one of the most common respiratory viruses in infants and young children, infecting almost all children by the age of 2 years old. RSV can …See details»
ABRYSVO: Pfizer Canada’s Newly Publicly Funded Vaccine a Step …
ABRYSVOâ„¢ was approved in December 2023 by Health Canada for the prevention of lower respiratory tract disease and severe lower respiratory tract disease caused by RSV. The …See details»
Canada approved multiple RSV shots to ward off infections this fall ...
Sep 18, 2024 · Health Canada has approved the first respiratory syncytial virus (RSV) vaccine for pregnancy to protect infants from birth to six months of age. Pfizer Canada's bivalent vaccine, …See details»
Health Canada approves 1st RSV vaccine for people 60 …
Aug 4, 2023 · Health Canada has approved the first vaccine for respiratory syncytial virus (RSV) for adults age 60 and over, but it may only be available in "limited" quantities for this fall's respiratory...See details»
What is RSV, and do I need a vaccine in Canada? | CTV News
Jul 16, 2024 · Health officials recently changed the guidelines for respiratory syncytial virus vaccines. Here's what Canadians need to know about the guidance and the virus itself.See details»
Efficacy and Safety of an mRNA-Based RSV PreF …
Dec 13, 2023 · Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized RSV prefusion F glycoprotein,...See details»
Respiratory Syncytial Virus - Ontario.ca
Respiratory syncytial virus (RSV) is a major cause of respiratory illness, particularly among infants, young children, and older adults, affecting the lungs and airways. RSV is the most …See details»
The road to approved vaccines for respiratory syncytial virus
Sep 25, 2023 · After decades of work, several interventions to prevent severe respiratory syncytial virus (RSV) disease in high-risk infant and older adult populations have finally been approved. …See details»
Respiratory syncytial virus (RSV) vaccines: Canadian Immunization …
Two vaccines are available to protect adults 60 years of age and older from RSV; RSVPreF3 (Arexvy) and RSVpreF (Abrysvo TM). RSV immunization should be considered for any infant …See details»
Safety and immunogenicity of mRNA-1345 RSV vaccine ... - The …
3 days ago · Coadministered mRNA-1345 plus SIIV4 or mRNA-1273.214 vaccines had acceptable safety profiles and elicited mostly non-inferior immune responses compared to …See details»
The new RSV vaccines for older adults - Mayo Clinic Press
Sep 19, 2023 · In May 2023, pharmaceutical companies GSK and Pfizer received approval from the U.S. Food and Drug Administration (FDA) for their RSV vaccines within weeks of each …See details»
RSV Vaccine Guidance for Older Adults | RSV | CDC - Centers for …
Aug 30, 2024 · Three RSV vaccines are currently available for adults ages 60 and older: GSK’s Arexvy, Moderna’s mResvia, and Pfizer’s Abrysvo. Eligible older adults may receive any of the …See details»
Summary: Statement on the prevention of respiratory syncytial
On May 15, 2024, the Public Health Agency of Canada (PHAC) released the National Advisory Committee on Immunization's (NACI) updated guidance on the prevention of respiratory …See details»
Health Canada approves RSV vaccine for maternal immunization
Jan 4, 2024 · Health Canada has approved a new Respiratory Syncytial Virus (RSV) vaccine geared toward protecting two of the groups most severely affected by the virus: newborns, …See details»
RSV Immunization Guidance for Infants and Young Children
Aug 30, 2024 · To prevent severe RSV disease in infants, either maternal RSV vaccination or infant immunization with the RSV monoclonal antibody (nirsevimab) is recommended. Most …See details»
RSV Prevention — Breakthroughs and Challenges - The New …
Dec 27, 2023 · In 2019, there were an estimated 33 million cases of acute lower respiratory tract infection due to RSV, resulting in 3.6 million hospitalizations and 26,300 in-hospital deaths …See details»
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults …
Oct 22, 2024 · Pfizer currently is the only company with an RSV vaccine to help protect adults aged 60 and older, and adults 18 and older at increased risk of lower respiratory tract disease …See details»